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Objectives: To prevent invasive fungal disease (IFD) in adult patients undergoing remission-induction chemo-
therapy for newly diagnosed acute lymphoblastic leukaemia (ALL).
Patients and methods: In a double-blind multicentre Phase 3 study, patients received prophylactic liposomal
amphotericin B (L-AMB) at 5 mg/kg intravenously or placebo twice weekly in a 2:1 random allocation during
remission-induction treatment. The primary endpoint was the development of proven or probable IFD.
Secondary endpoints included those focused on the safety and tolerability of prophylactic L-AMB.
Results: Three hundred and fifty-five patients from 86 centres in Europe and South America received at least
one dose of L-AMB (n"237) or placebo (n"118). Rates of proven and probable IFD assessed independently
were 7.9% (18/228) in the L-AMB group and 11.7% (13/111) in the placebo group (P"0.24). Rates of possible IFD
were 4.8% (11/228) in the L-AMB and 5.4% (6/111) in the placebo group (P"0.82). The remission-induction
phase was a median of 22 days for both groups. Overall mortality was similar between the groups: 7.2%
(17/237) for L-AMB and 6.8% (8/118) for placebo (P"1.00). Hypokalaemia and creatinine increase were signifi-
cantly more frequent with L-AMB.
Conclusions: The IFD rate among adult patients undergoing remission-induction chemotherapy for newly diag-
nosed ALL was 11.7% in the placebo group, and was not significantly different in patients receiving L-AMB, suggest-
ing that the L-AMB regimen studied is not effective as prophylaxis against IFD. The IFD rate appears higher than
previously reported, warranting further investigation. Tolerability of L-AMB was what might be expected. Further
studies are needed to determine the optimal antifungal strategy during remission-induction chemotherapy of ALL.
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please email: journals.permissions@oup.com.
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Introduction
Adult patients with acute lymphoblastic leukaemia (ALL) are given
intensive multidrug chemotherapy to induce remission based on
paediatric protocols of 6–8 weeks duration.1 During this period, pa-
tients are at risk of invasive fungal disease (IFD) due to neutropenia
and exposure to high-dose glucocorticosteroids.1–3 IFD is challeng-
ing to diagnose, particularly in the early stages, when symptoms
and signs are absent or non-specific.4 Moreover, IFD has consider-
able impact on morbidity and mortality, and may interrupt or delay
chemotherapy, consequently reducing dose intensity and com-
plete and molecular remission rates.1,2 Antifungal prophylaxis
could potentially contribute to treatment efficacy.5,6
An IFD rate of 6.5% has been reported in a retrospective ana-
lysis of adult ALL patients, with aspergillosis and candidiasis pre-
dominating.2 An IFD rate of 8.8% has been reported in ALL
patients with neutropenia,7 and a rate of 6.7% has been identified
in patients receiving induction chemotherapy for the treatment of
ALL.8 While prophylaxis with azole antifungals has been developed
for other patient groups at similar risk, there is currently no
approved standard of care for patients with ALL.9,10 The European
Working Group for Adult ALL (EWALL) recommends that azole
antifungals should be avoided because of drug–drug interactions
with vinca alkaloids, a key component of ALL chemotherapy regi-
mens.1 Liposomal amphotericin B (L-AMB) offers an alternative as
it is active against a broad variety of fungi, including Aspergillus
species, Candida species and agents of mucormycosis.6,11–13
Support for L-AMB use in treatment comes from studies examining
its pharmacokinetics in animal models, healthy volunteers and
neutropenic patients at doses between 1 and 7.5 mg/kg/day and
knowledge that it has a long terminal elimination half-life.14–16
L-AMB is not licensed for prophylaxis, but small prophylaxis studies
in neutropenic patients that used different, mostly intermittent,
dosing regimens have demonstrated a trend towards a reduced
incidence of IFD.17–21 However, doses .5 mg/kg were associated
with an increased incidence of infusion-related reactions.18
The medical need for antifungal prophylaxis was identified in
close collaboration with EWALL. The AmBiGuard study was de-
signed to determine the efficacy and safety of L-AMB given at
5 mg/kg twice weekly compared with placebo to prevent IFD in
adults undergoing remission-induction chemotherapy for newly
diagnosed ALL.
Patients and methods
The study was conducted at 86 centres in 13 countries in Europe and South
America and registered on clinicaltrials.gov (NCT01259713) and EudraCT
(2010-019562-91). The study was conducted in accordance with the
Declaration of Helsinki. The protocol was approved by the institutional review
board of each participating site. Written informed consent was obtained
from each patient. An independent data safety monitoring board (DSMB)
supervised the study and undertook a planned interim data review for futility
when half the subjects had completed the study. An independent data re-
view board (IDRB) performed a blinded review of data from all patients to as-
sess the presence of IFD according to the revised consensus definitions.4
Eligibility criteria
Adults 18 years were eligible provided they were to receive remission-
induction chemotherapy for newly diagnosed ALL that was likely to induce
10 days of neutropenia (absolute neutrophil counts ,500/lL), and were
able to start the study drug within 5 days of the first dose of chemotherapy.
Patients were excluded if there was clinical suspicion of IFD including unex-
plained fever, evidence of pulmonary infiltrates on imaging or if they had
been given antifungal treatment in the previous 30 days. Patients were also
excluded if their serum creatinine was .2 times the upper limit of normal
(ULN), liver function tests were .5%ULN22 or if there was any severe
comorbidity or any hypersensitivity to amphotericin B.
Study drug
The colour and overall appearance of L-AMB and placebo (riboflavin 50 phos-
phate formulated in soy phosphatidylcholine as liposomes) did not differ.
The two drugs were prepared and given in the same manner. Study person-
nel were blinded to treatment allocation. A blinded member of the phar-
macy staff prepared the solutions and provided blind-labelled infusion bags
for administration. L-AMB was given at a dose of 5 mg/kg based on the pa-
tient’s weight at screening and dose adjustment to weight changes was
allowed. This dose was selected in order to minimize toxicity. Study drug
was infused over 2 h twice weekly (3–4 day interval) during the entire
remission-induction phase of chemotherapy. The dosing schedule was
chosen on practical grounds.
IFD monitoring and diagnostic-driven
antifungal treatment
Patients underwent prospective monitoring for the development of IFD ac-
cording to defined study algorithms throughout the duration of the study
and for the 30 days after stopping the study drug (Figures S1–S3, available
as Supplementary data at JAC Online). Serum samples were drawn twice
weekly and tested for galactomannan (GM) and 1,3-b-D-glucan (BDG) cen-
trally in Belgium, Argentina or Brazil. The results were reported to the site
within 48–72 h. A thoracic CT scan was recommended when the myco-
logical criteria were met for a proven or probable IFD, and the study algo-
rithm was followed according to the result (Figure S2).23 When no
mycological criteria were met,4 a work-up was undertaken when patients
had unexplained fever (temperature 38C for 72 h) despite antibiotic
treatment, relapsing fever, new pulmonary infiltrates on chest X-ray or
other potential signs and symptoms of IFD (Figure S3).
Systemically active antifungal agents were not permitted except for pa-
tients who developed oropharyngeal candidiasis despite topical measures;
they were allowed to receive concomitant oral fluconazole at 100–200 mg
for 10 days.
Study treatment was replaced for up to 5 days with an antifungal other
than amphotericin B when there were findings suggestive of IFD to allow
further diagnostic tests to be done. Treatment was stopped and prophy-
laxis restarted when these tests proved negative. Protocol-specified criteria
to stop prophylaxis and start broad-spectrum antifungals were defined.
Study procedures
All concomitant medications, including chemotherapy and other anti-
microbials, were recorded from 30 days before recruitment and until study
completion. All adverse events (AEs) were recorded up to 30 days from last
dose, regardless of their potential relationship to the study drug. Laboratory
assessments (haematology and chemistry) and complete or symptom-
directed physical examinations, including vital signs and temperature, were
done at scheduled times.
Study treatment ended for the patient when one of the following
occurred: (i) diagnosis of a proven or probable IFD; (ii) remission-induction
chemotherapy was completed, neutropenia resolved and the patient was





Amphotericin B serum trough concentrations were determined in a subset
of patients.
Efficacy and safety endpoints
The primary efficacy endpoint was the development of proven or probable
IFD during remission-induction chemotherapy, measured as the proportion
of patients who met this endpoint as assessed by the IDRB. Secondary end-
points included: the proportion in complete remission at last follow-up
(e.g. 30 days after end of study treatment); the time to diagnosis of proven
or probable IFD; the proportion that required antifungal treatment accord-
ing to protocol guidance; the proportion of patients who developed pul-
monary infiltrates; the proportion of patients with proven IFD and probable
IFD;4 and the number of deaths due to IFD as assessed by the IDRB.
Additionally, the development of AEs and abnormal clinical laboratory re-
sults were examined.
Randomization, sample size and statistical methods
Patients who met the eligibility criteria were randomized, using an inter-
active voice or web response system, to receive either 5 mg/kg L-AMB or
matched placebo twice weekly. Randomization was done centrally and
stratified by geographical region: Europe versus South America using per-
muted blocks (Table S1).
The intended sample size (n"354) was based on having 81% power to
detect a 75% relative reduction in IFD in the L-AMB group, assuming a rate
of IFD of 10% in the placebo group using a Cochran–Mantel–Haenszel
(CMH) test with a 0.05 two-sided significance level and 2:1 allocation. The
assumed IFD rate of 10% for the placebo group is in line with previously re-
ported prophylaxis studies in other patient populations at high risk of
IFD.10,24,25 A 0.05 two-sided test was chosen because the interim bounda-
ries were based around a two-sided test. We selected 2:1 randomization of
L-AMB to placebo rather than 1:1 randomization due to ethical consider-
ations and its potential to provide more comprehensive safety data for the
L-AMB group.
The primary efficacy analysis used the ITT population, i.e. all subjects
who were randomly allocated to study treatment, who received at least
one dose of study drug and met the major eligibility criteria (newly diag-
nosed with ALL and had not received systemically active antifungals within
the previous 30 days). An ITT analysis excluding patients who were never
neutropenic was done as was a post hoc per-protocol analysis set excluding
patients receiving antifungals not permitted by the protocol. The safety
analysis population included all patients who received at least one dose of
the randomly allocated study drug.
All statistical tests were performed at the 0.05 level (unless otherwise
stated) without consideration for multiplicity. The CMH test was used for
the primary analysis after adjusting for region.
A planned interim analysis for futility was undertaken when 50% of pa-
tients had completed the study, so a for the primary analysis was adjusted
by 0.0003.
Categorical secondary efficacy endpoints including the proportion of pa-
tients diagnosed with proven or probable IFD were analysed using a non-
stratum-adjusted relative risk reduction. The time to diagnosis of proven or
probable IFD and the duration of remission-induction chemotherapy were
analysed using Kaplan–Meier estimates and the log rank test, after stratify-
ing by region. A P value of ,0.05 was considered statistically significant.
Results
From April 2011 to November 2013, 391 patients were screened
and 360 were enrolled. Five patients were not treated and 16 failed
to meet the entry criteria, i.e. 15 received protocol-prohibited sys-
temic antifungal treatment in the 30 days prior to first dose of
study drug and 1 did not have ALL. Hence, 339 patients were
included in the efficacy analysis. The safety analysis comprised
355 patients who received at least one dose of study drug
(Figure 1), of whom 237 were randomly allocated to receive L-AMB
and 118 to receive placebo.
Demographic and baseline characteristics were similar
across the treatment groups (Table 1). The median age was
46 (IQR 30–58) years. Commonly used constituents of chemother-
apy for remission induction included cytarabine, cyclophospha-
mide, vincristine and anthracyclines, particularly daunorubicin and
idarubicin. Systemic glucocorticosteroids were part of the chemo-
therapy in the majority of patients [L-AMB 90.4% (206/228),
placebo 91.0% (101/111)]. Over 90% of subjects received twice-
weekly infusions of study drug as specified in the protocol.
Efficacy analyses
Rates of proven/probable IFD as assessed by the IDRB (primary end-
point) were 7.9% (18/228) in the L-AMB and 11.7% (13/111) in the
placebo group (P"0.24), suggesting that L-AMB is not effective as
prophylaxis against IFD in these patients. The remission-induction
phase was a median of 22 days for both groups. Additionally, rates
of possible IFD were 4.8% (11/228) in the L-AMB and 5.4% (6/111)
in the placebo group (P"0.82) (Table 2, Table S2).
The IFD incidence rates for patients who were neutropenic for
10 days (n"258) were 6.9% in the L-AMB group versus 13.1% in
the placebo group (P"0.10) (Table 2; Table S3).
Subgroup analyses of the primary endpoint showed that the
proportion of patients with proven or probable IFD was consist-
ently lower in the L-AMB group than in the placebo group
(Figure S4). Time to diagnosis of IFD was not significantly different
between the two study groups (P"0.33) (Figure 2).
Chest CT scans were done for 82 (36.0%) patients in the L-AMB
group and 51 (45.9%) patients in the placebo group. Antifungal
treatment was given during remission-induction chemotherapy to
16.2% (37/228) patients in the L-AMB group and 21.6% (24/111) in
the placebo group (P"0.22). These treatments were considered
protocol violations in eight patients in each group.
Overall mortality was similar between the groups, being 7.2%
(17/237) in the L-AMB group and 6.8% (8/118) in the placebo
group (P"1.00) (Figure S5). Two deaths in the L-AMB group were
attributed to IFD by the IDRB (probable invasive pulmonary asper-
gillosis and proven candidaemia), but none in the placebo group.
Most patients in each group were neutropenic (,500/lL) dur-
ing remission-induction chemotherapy (L-AMB 90.8%; placebo
92.8%), and 76.3% and 75.7% were neutropenic for 10 days.
Median duration of neutropenia ,500/lL was 18 days for both
groups (IQR L-AMB 13.0–26.0, placebo 11.0–25.0 days). The ab-
solute neutrophil count nadir was ,100/lL in 167 (73.2%) pa-
tients in the L-AMB group and 82 (73.9%) patients in the placebo
group.
There was no significant difference in the median duration of
neutropenia.
Complete remission rates were lower in the L-AMB group
[72.8% (166/228)] than in the placebo group [79.3% (88/111)], al-
though not significantly so (P"0.20).
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Post hoc efficacy analysis on patients without major
protocol deviations
For this analysis, a total of 44 patients in the L-AMB group and 21 in
the placebo group were excluded from the ITT analysis set be-
cause of at least one protocol deviation that could have influenced
the primary endpoint. This included 41 patients who received sys-
temic antifungals in violation of the protocol (24 L-AMB versus
17 placebo), 2 patients in the L-AMB group with baseline IFD and
28 patients who had not been given regimens expected to induce
10 days of neutropenia (21 L-AMB versus 7 placebo). IFD rates in
the remaining 274 patients were 7.6% (14/184) in the L-AMB
group and 14.4% (13/90) in the placebo group (P"0.07).
Pharmacokinetic analyses
A total of 175 trough pharmacokinetic samples were collected
from 27 patients given L-AMB between 1.4 and 6.4 days after the
previous dose of study drug. Mean+ SD trough serum concentra-
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Figure 1. CONSORT flow diagram. Of 360 subjects randomized, 5 were never dosed, and 16 (9 L-AMB, 7 placebo) were excluded from the efficacy
analysis, 1 due to misdiagnosis (AML) and 15 due to protocol-prohibited antifungal treatment either concomitant with or within the previous 30 days.
Table 1. Patient baseline characteristics
Characteristic L-AMB (N"237) Placebo (N"118) P valuea
Age (years), median (IQR) 45 (32–57) 47 (28–60) 0.82
Male, n (%) 139 (59) 60 (51) 0.16
White, n (%) 211 (89) 100 (85) 0.25
Weight (kg), median (IQR) 74.0 (66.0–84.0) 74.7 (62.3–87.9) 0.92
Height (cm), median (IQR) 170.0 (164.0–178.0) 170.0 (164.0–179.0) 0.94
BMI (kg/m2), median (IQR) 25.2 (22.7–28.7) 25.0 (22.0–28.7) 0.76
Baseline ANC (cells/lL), median (IQR) 820 (270–1880) 560 (210–1610) 0.27
Patient ANC distribution, n (%)
,200 cells/lL 49 (21.2) 26 (22.8)
200 to , 500 cells/lL 34 (14.7) 28 (24.6)
500 to , 1500 cells/lL 79 (34.2) 26 (22.8)
1500 cells/lL 69 (29.9) 34 (29.8)
Median days between start of remission induction and first dose of study drug (IQR) 3 (2–4) 3 (2–4) 0.55
ANC, absolute neutrophil count.




Of 355 patients treated, 61.7% (219/355) completed study drug
treatment for the planned duration: L-AMB 59.9% (142/237) and
placebo 65.3% (77/118) (P"0.36) (Table 3). Patients in both treat-
ment groups remained on study drug for a median 22 days (IQR
L-AMB 15–32, placebo 15–36 days). The reasons for premature
Table 2. Invasive fungal disease rates
Patient population L-AMB Placebo P valuea
IFD assessment by IDRB N"228 N"111
Proven or probable IFD (primary endpoint) 18 (7.9%) 13 (11.7%) 0.24
proven candidaemia 1 (0.4%)b 3 (2.7%)c 0.07
proven filamentous IFD 0 0
probable IFD 17 (7.5%) 10 (9.0%) 0.60
Possible IFD 11 (4.8%) 6 (5.4%) 0.82
Pulmonary infiltrates 46 (20.2%) 30 (27.0%) 0.15
Deaths due to IFD 2 (0.9%)d 0 0.32
IFD assessment by investigator N"228 N"111
Proven or probable IFD 25 (11.0%) 12 (10.8%) 0.97
Requirement for antifungal treatment 37 (16.2%) 24 (21.6%) 0.22
Deaths due to IFD 2 (0.9%) 0 0.32
Post hoc analysis on patients without major protocol deviationse N"184 N"90
Proven or probable IFD 14 (7.6%) 13 (14.4%) 0.07
Neutropenic for10 days (ANC ,500 cells/lL) N"174 N"84
Proven or probable IFD 12 (6.9%) 11 (13.1%) 0.10
ANC, absolute neutrophil count.
Three subjects (one L-AMB, two placebo) had Pneumocystis spp. in bronchoalveolar lavage (BAL) and were not considered to have IFD as it is not part
of the EORTC/MSG criteria.
aStratum-adjusted (stratified by region) CMH test.
bC. kefyr.
cC. albicans (2%), C. tropicalis bloodstream infections.
dProbable invasive pulmonary aspergillosis, proven candidaemia.
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Figure 2. Time to diagnosis of invasive fungal disease as assessed by the independent data review board.
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discontinuation of study drug were similar in the two groups, most
commonly because of an AE, the investigator’s discretion or with-
drawal of consent. Most patients had at least one AE and a similar
proportion of patients in each group had AEs of grade 3 or
higher.16,20 Most patients in each group had AEs considered by the
investigator to be related to ALL or to chemotherapy. A similar pro-
portion of patients in each group had AEs considered to be related
to IFD or AEs that resulted in premature discontinuation of the
study drug. More patients in the L-AMB group had an AE that re-
sulted in interruption of treatment with the study drug (20.3% ver-
sus 7.6%; P"0.002), and experienced serious AEs (Table S4)
considered related to study drug by the investigator (8.4% versus
1.7%; P"0.02). Statistically significantly more patients were af-
fected by hypokalaemia and elevated creatinine in the L-AMB
group (Table 3).
Discussion
This large, randomized, double-blind, placebo-controlled study,
using a pre-specified diagnostic algorithm, showed that almost
1 in 11 patients receiving remission-induction chemotherapy for
ALL developed a probable or proven IFD. This is almost twice the
rate reported in a retrospective cohort study2 and is of the same
order of magnitude as reported for patients receiving remission-
induction therapy for AML without mould-directed antifungal
prophylaxis.10 The observed incidence in this study is also towards
the upper end of IFD rates reported in other retrospective case col-
lections in patients with ALL of between 6.5% and 8.8%.2,7,8 It is
therefore important to consider the potential factors behind this
possibly high observed incidence, which resulted from a prospect-
ive trial with a well-designed diagnostic algorithm.
Neutropenia and prolonged treatment with glucocorticoste-
roids are considered host factors that may contribute to the high
incidence of IFD observed.4 Another factor may be the inclusion of
non-culture-based methods in our diagnostic strategy, which may
have led to a higher number of cases of IFD being identified. In any
event, the high incidence observed clearly warrants further investi-
gation and consideration of appropriate preventative measures,
including antifungal prophylaxis.
Our study failed to show that twice-weekly dosing of L-AMB
5 mg/kg significantly reduced the IFD rate, which is difficult to ex-
plain since L-AMB is effective in treating IFD.11–13 The dose used
was chosen to minimize toxicity but may not have been high
enough to be effective, representing a major limitation of the
study. However, despite the low dose (half the standard treatment
dose of 3 mg/kg/day), the number of withdrawals due to AEs and
the number of serious AEs were both much higher with L-AMB
than with placebo. The dosing interval was chosen on practical
grounds and may have been too long, although pharmacokinetic
analysis showed that L-AMB trough concentrations were
Table 3. Adverse events as assessed by the investigators21
Adverse events, n (%) L-AMB (N"237) Placebo (N"118) P valuea
Any treatment-emergentb AE 237 (100) 115 (97.5) 0.036
pyrexia 67 (28.3) 40 (33.9) 0.33
hypotension 18 (7.6) 15 (12.7) 0.12
Treatment-emergentb renal AEs
hypokalaemia, any grade 83 (35.0) 21 (17.8) ,0.001
,LLN (3.0 mmol/L) 45 (19.0) 12 (10.2) 0.03
,LLN (3.0 mmol/L); symptomatic, intervention indicated 25 (10.5) 6 (5.1) 0.11
,3.0–2.5 mmol/L 10 (4.2) 2 (1.7) 0.35
,2.5 mmol/L 3 (1.3) 1 (0.8) 1.00
creatinine increase, any grade 22 (9.3) 0 ,0.001
.1 to 1.5% baseline; .ULN to 1.5%ULN 7 (3.0) 0 0.10
.1.5 to 3.0% baseline; .1.5 to 3.0%ULN 15 (6.3) 0 0.003
.3.0% baseline; .3.0 to 6.0%ULN 0 0 1.00
Other AE categories
serious adverse events (SAEs) 79 (33.3) 38 (32.2) 0.90
SAE related to study drug, any grade 20 (8.4) 2 (1.7) 0.02
AE leading to study drug interruption 48 (20.3) 9 (7.6) 0.002
AE leading to study drug discontinuation 63 (26.6) 26 (22.0) 0.37
any grade 3 AE 102 (43.0) 43 (36.4) 0.25
any grade 4 AE 69 (29.1) 40 (33.9) 0.39
AE related to death 17 (7.2) 8 (6.8) 1.00
AE related to ALL or ALL treatments 226 (95.4) 110 (93.2) 0.45
AE related to IFD 17 (7.2) 10 (8.5) 0.67
LLN, lower limit of normal; ULN, upper limit of normal.
aFisher’s exact test.
bTreatment emergent is defined as started on or after first dose and up to 30 days after last dose of study drug.
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adequate.26,27 Better understanding of the pharmacokinetics of
L-AMB is therefore necessary to identify the most appropriate dos-
age for prophylaxis.
Other factors to consider include the point that the 10% esti-
mate of the IFD rate for the placebo group was exceeded, but ex-
pecting a 75% reduction in IFD incidence in the sample size
calculation may have been too optimistic.10,24,25 Attrition of statis-
tical power due to protocol deviations may provide a further
explanation.
Some patients were included although they received regimens
that did not induce severe neutropenia, and others received sys-
temic antifungal agents in violation of the protocol despite de-
tailed management algorithms for suspected IFD that may have
impacted the assessment of the primary endpoint. This early anti-
fungal treatment may have caused false negativity of the
diagnostic-driven strategy applied. Post hoc analyses of the group
of patients without substantial protocol deviations showed that
the difference between treatment groups was more pronounced,
though this did not reach statistical significance. The lack of neu-
tropenia in subjects was not explained by the use of growth
factors.
Complete remission rates were lower than expected, but this is
likely to be due to evaluation of subjects before the end of induc-
tion/beginning of consolidation and to some subjects being lost to
follow-up (Figure 1).
Mortality was very similar in both treatment groups (7.2% ver-
sus 6.8%), and deaths in the placebo group were not attributed to
IFD by the investigators. The diagnostic-driven strategy may pick
up IFD earlier at a more effectively treatable stage. Because the
trial did not reveal a difference in overall mortality or in mortality
attributable to IFD, a diagnostic-driven treatment approach may
be a more suitable strategy in this specific patient population.
While prophylaxis is beneficial for patients receiving remission-
induction chemotherapy for AML,10 heightened clinical awareness
combined with intensive microbiological screening may be appro-
priate for those undergoing similar treatment for ALL.
L-AMB was not effective in preventing IFD in patients receiving
remission-induction chemotherapy for ALL. Tolerability of L-AMB
was what might be expected but further studies are clearly needed
to determine whether a change in dosing might have yielded bet-
ter results. Nonetheless, the rate of IFD found in this study was
higher than that reported in previous studies; however, whether
prophylaxis is the best antifungal strategy during remission-
induction chemotherapy of ALL, or whether the use of a
diagnostic-driven approach combining intensive clinical and
microbiological screening to detect IFD at an early stage would be
more appropriate, remains to be seen. Finally, even though L-AMB
given as prophylaxis did not prove effective in our study, this should
not deter others from exploring this subject further, given the high
incidence of IFD in this patient population.
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